Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Study Summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Conditions

Obesity and Overweight

Interventions / Drugs

MET097 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment3500 participants

Primary Completion—

Lead SponsorMetsera, a wholly owned subsidiary of Pfizer

Data Retrieved2026-04-11 02:55:53.190390+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.